medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2011, Number 3

<< Back Next >>

Rev Mex Urol 2011; 71 (3)

Genomic rearrangement analysis in aggressive prostate cancer

Garza-Cortez R, Cárdenas-Cadena SA, Gómez-Guerra LS, Garza-Guajardo R, Ortíz-López R, Grondin Y, Leach RJ, Reveles XT, Rojas-Martínez A

Language: Spanish
References: 15
Page: 160-163
PDF size: 372.98 Kb.


ABSTRACT

Initial stages of prostate cancer are a clinical challenge due to the lack of tumor progression biomarkers that define whether the tumor will remain localized or will become aggressive and lethal. In the present study, a gains and losses analysis of chromosomal regions was carried out on two sample groups (aggressive prostate cancer and nonaggressive prostate cancer) to identify loci associated with aggressive or non-aggressive prostate cancer progression.
Methods: Microarray based comparative genomic hybridization was carried out in paraffin-embedded DNA samples of prostatic tissue (primary tumor) from patients diagnosed with aggressive prostate cancer (n = 15) and with non-aggressive prostate cancer (n = 8). Data resulting from array comparative genomic hybridization were analyzed using R software non-supervised grouping (k-median centroids) and supervised grouping (reduced centroids).
Results: Non-supervised grouping was not correlated with prostate cancer aggressiveness. A classifying profile of approximately one hundred and fifty chromosomal regions with a 30% classification error and 20% false positives was obtained through supervised grouping.
Conclusions: Multiple loci with and without previous reports of aggressive prostate cancer association were found. Due to small sample size a more extensive analysis should be carried out to confirm association of those regions with prostate cancer aggressiveness.


REFERENCES

  1. Organización Mundial de la Salud (OMS) GLOBOCAN 2008 (IARC) Section of Cancer Information (17/8/2010).

  2. Baird DM. Variation at the TEST locus and predisposition for cancer. Expert Rev Mol Med. 2010 May 18;12:e16.

  3. Marian CO, Wright WE, Shay JW. The effects of telomerase inhibition on prostate tumor-initiating cells. Int J Cancer. 2010 Jul 15;127(2):321-31.

  4. Sun J, Liu W, Adams TS, et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007;67:692-700.

  5. Ishkanian AS, Mallof CA, Ho J, et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009;69:1091-100.

  6. Morichetti D, Mazzucchelli R, Santinelli A, et al. Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. Int J Immunopathol Pharmacol 2010;23:511-22.

  7. Halmos G, Schally AV, Sun B, et al. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 2000;85:2564-71.

  8. Ghoussaini M, Song H, Koessler T, et al. Multiple Loci With Different Cancer Specificities Within the 8q24 Gene Desert. J Natl Cancer Inst 2008;100:962-6.

  9. Lin D, Watahiki A, Bayani J, et al. ASAP1, a gene at 8q24, is associated with prostate cancer metastasis. Cancer Res 2008;68:4352-9.

  10. Di Vizio D, Morello M, Sotgia F, et al. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009;8:2420-4.

  11. Wong SY, Haack H, Kissil JL, et al. Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci USA 2007;104:12784-9.

  12. Bernkopf DB, Williams ED. Potential role of EPB41L3 (protein 4.1B/ Dal-1) as a target for treatment of advanced prostate cancer. Expert Opin Ther Targets. 2008 Jul;12(7):845-53.

  13. Wu K, Katiyar S, Witkiewicz A, et al. The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res 2009;15:3347-55.

  14. Rose AE, Satagopan JM, Oddoux C, et al.Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med 2010;22:70.

  15. van Duin M, van Marion R, Vissers K, et al. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 2005;44:438-49.




2020     |     www.medigraphic.com